



Incanthera is developing innovative technologies for oncology and dermatology

www.incanthera.com

Incanthera (INC:AQSE) is dedicated to improving treatment options with innovative technologies in oncology and dermatology.

Inspirational therapeutics, combined with uniquely targeted delivery technologies show the potential to transform the future of health care.

The company was founded in 2010, as a spin out from the Institute of Cancer Therapeutics (ICT) at the University of Bradford with the aim of bringing innovative novel technologies to patients.

RICH PIPELINE

The ICT has created and continues to offer a rich pipeline of tumour-targeting drug delivery systems and technologies and Incanthera's portfolio includes technologies both from the ICT and from commercial licensing and acquisition partnerships.

Today, with an established oncology pipeline and a successful first year as a publicly listed company, the company marks the success of another unique technological approach, with skin cancer formulation, Sol.

Sol combines oncology and dermatology, through the application of modern



TODAY... THE COMPANY MARKS THE SUCCESS OF ANOTHER UNIQUE TECHNOLOGICAL APPROACH, WITH SKIN CANCER FORMULATION, SOL.

formulation capabilities and delivery mechanisms that surpass expectations.

Discussions with two global cosmetics companies for a potential licensing partnership progress and

the company looks forward to updating the market when further able.

Incanthera's business model is to acquire the best technologies, prepare them using Incanthera's expertise, partnerships and relationships and commercialise at the earliest opportunity, whilst ultimately delivering enhanced treatment options to patients.

This unique model is intended to deliver: better, faster therapies to patients; faster; de-risked returns to investors.

Incanthera floated on the Aquis Exchange in February 2020, raising £1.4 million to progress its lead asset Sol, an innovative topical product developed for the treatment of solar keratosis and the prevention of skin cancers.

STRATEGIC PROGRESS

The investment received at the IPO allowed progression and refinement of Sol's formulation to deliver exceptional permeation and sensitisation study results, as reported in September 2020.

The study results proved beyond doubt that Sol has a unique capability to permeate the skin barrier and deliver effective treatment at the site of pre-cancerous

and cancerous conditions in a formulation that is as non-irritant as some currently marketed baby sun protection products.

This is breakthrough news for skin cancer patients, offering a targeted and safe approach and an opportunity to prevent development of skin cancer.

PROVEN EFFICACY

The combined package of proven efficacy and safety delivers an even stronger commercial profile, which has concentrated discussions towards a potential licensing partnership. This is further enhanced by the filing in July 2020 which will protect Sol's technology until 2040.

Discussions with global cosmetics companies for a potential licensing partnership progress and the company looks forward to updating the market when further able.

Incanthera published its full year results to 31 March 2021 in May 2021, with the emphasis on operational success.

The public listing on AQSE last year provided a platform to engage long-term shareholders in opportunities for the future, but also to bring in new investment, which has been further enhanced by a recently oversubscribed placing from new and institutional investors to raise £1.14 million.

Incanthera's operational successes and delivery of returns to shareholders resulted in the successful placing, putting the company in an excellent position to conclude Sol discussions and to look



THIS IS BREAKTHROUGH NEWS FOR SKIN CANCER PATIENTS, OFFERING A TARGETED AND SAFE APPROACH AND AN OPPORTUNITY TO PREVENT DEVELOPMENT OF SKIN CANCER.

at the promise that the technologies and delivery mechanisms can bring to future commercial success. The Incanthera team led by Simon Ward, chief executive officer and chairman Tim McCarthy, possesses a broad range of skills and talent, which has produced successful results.

The continued support of shareholders and the new investment in the company is testament to the achievements and enormous potential in the

existing portfolio and the opportunities for the future.

Incanthera looks forward to continuing to enhance and build its expertise and ability to bring novel medicines to patients.

